Vaccines

Harrow partners with specialist LogiCare3PL for U.S. distribution, highlighting an industry shift towards agile, high-touch logistics for faster market access.

Eli Lilly acquires CrossBridge Bio for its innovative dual-payload ADC platform, signaling a major push into the next wave of targeted cancer treatments.

A new once-daily pill for hypoparathyroidism begins human testing, promising to replace burdensome injections and transform patient care. Is this the future?

With new funding, ImageneBio advances its unique OX40 inhibitor, IMG-007, for eczema and alopecia, but faces a divided Wall Street.

Orum Therapeutics adds deep clinical and dealmaking expertise to its board, signaling a strategic acceleration of its innovative DAC pipeline for cancer.

Replimune halts a promising cancer therapy and cuts jobs after a stunning FDA rejection, citing a 'failed' system and inconsistent regulatory process.

Lupin has launched a generic version of the blockbuster diabetes drug Farxiga, signaling lower costs for patients and a major shake-up in the SGLT2 market.

Ceva Animal Health appoints former Virbac CEO Sébastien Huron as Deputy CEO, creating a dual leadership aimed at accelerating growth and operational might.

Ditching the static model, CleanSpace is building a full-scale, operational pharmaceutical factory on the tradeshow floor, a move set to transform B2B marketing.

Five new clinical trials in Chicago repurpose existing drugs for PTSD, cancer, and more, offering a faster, cheaper path to treating unsolved diseases.

With late-stage trials for two common eye conditions affecting millions, Cloudbreak Pharma is advancing novel drops where no approved drugs exist.

Positive Phase 1b data for two novel drugs suggests a long-acting, once-monthly oral therapy for recurrent genital herpes may be on the horizon.

An exclusive partnership between Osmind and CareNet GPO gives small practices the power of large systems, aiming to broaden patient access to advanced mental healthcare.

OncoC4 begins a landmark trial for ONC-841, a drug targeting immune cells in the brain, offering a new front in the fight against Alzheimer's disease.

A Swiss biotech's novel antibiotic has entered human trials with new funding, offering a fresh hope against the world's most dangerous superbugs.

A new paper warns that Lyme disease may pass from mother to child, a risk overlooked for decades. Researchers are now demanding urgent action and funding.

With its lead drug in Phase 3 and a strong Biogen partnership, Stoke Therapeutics prepares to update investors on its disease-modifying Dravet syndrome therapy.

A single-dose therapy wiped out aggressive glioblastoma tumors in a landmark pre-clinical study, paving the way for human trials in 2026.

With stellar trial data for its cholesterol drug obicetrapib, NewAmsterdam Pharma faces investors as it navigates a competitive market and awaits key results.

Ovid Therapeutics is spotlighting a novel drug class targeting KCC2, a key brain protein. Could this be the key to treating psychosis and epilepsy?